|
Palo Alto, CA, May 23, 2005 — Telik, Inc. (Nasdaq: TELK) announced that company management will provide corporate updates at the UBS Global Pharmaceuticals Conference on Tuesday, May 24 at 9:00 am EDT, and at the Fourth Annual Needham Biotechnology Conference on Wednesday, May 25 at 9:00 am EDT. Both conferences will be held in New York City. Live webcasts of the presentations will be available on the Telik website, www.telik.com. An archived webcast will be accessible on the Telik site through
June 1, 2005.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA™ (TLK286), a tumor-activated small molecule product candidate which is in three Phase 3 registration trials in advanced ovarian and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2005 Press Releases2004
Press Releases
2003
Press ReleasesEvents |
